Strategic partnerships Fortis Life Sciences operates in biotechnology with a focus on antibody discovery and single-domain antibodies (VHH), presenting strong potential for collaboration with pharma and biotech firms needing early stage drug discovery, antibody screening, and custom library services.

Expanded capabilities Recent launches and collaborations, including the AbNano VHH NK cell library and partnerships with Deliver Bio and Astraea Bio, indicate a growing portfolio in NK cell targeting, spatial biology, and multi-omics applications that can be upsold to organizations pursuing advanced translational research.

R&D focus With a robust phage display platform leveraging naïve and immunized libraries and a revenue range in the mid tens of millions, there is opportunity to offer tiered discovery services, custom antibody libraries, and accelerated screening programs to larger biopharma clients seeking efficiency gains.

Technology relevance Utilize Fortis Life Sciences' VHH libraries and LFA kit advancements to target diagnostics, point-of-care products, and translational research partnerships, presenting cross-sell opportunities to clinical labs, CROs, and diagnostic developers.

Funding signals Active investment in VHH discovery programs and external grants suggests readiness for co-development deals, joint ventures, and grant-backed collaborations that reduce client risk while expanding portfolio reach into NK cell–related therapies and targeted delivery platforms.